Identification
- Generic Name
- 4-Bromo-2,5-dimethoxyamphetamine
- DrugBank Accession Number
- DB01484
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental, Illicit
- Structure
Structure for 4-Bromo-2,5-dimethoxyamphetamine (DB01484)
- Weight
- Average: 274.154
Monoisotopic: 273.036441408 - Chemical Formula
- C11H16BrNO2
- Synonyms
- Not Available
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your software1,2-Benzodiazepine The risk or severity of CNS depression can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with 1,2-Benzodiazepine. Acebutolol The therapeutic efficacy of Acebutolol can be decreased when used in combination with 4-Bromo-2,5-dimethoxyamphetamine. Aceclofenac The risk or severity of hypertension can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Aceclofenac. Acemetacin The risk or severity of hypertension can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Acemetacin. Acenocoumarol The risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Acenocoumarol. - Food Interactions
- Not Available
Categories
- Drug Categories
- Agents producing tachycardia
- Agents that produce hypertension
- Amines
- Amphetamines
- Antidepressive Agents
- Central Nervous System Agents
- Central Nervous System Depressants
- Ethylamines
- Hallucinogens
- Neurotransmitter Agents
- Phenethylamines
- Psychotropic Drugs
- Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
- Serotonin Agents
- Serotonin Receptor Agonists
- Sympathomimetics
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as amphetamines and derivatives. These are organic compounds containing or derived from 1-phenylpropan-2-amine.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Phenethylamines
- Direct Parent
- Amphetamines and derivatives
- Alternative Parents
- Dimethoxybenzenes / Phenylpropanes / Phenoxy compounds / Anisoles / Bromobenzenes / Aralkylamines / Alkyl aryl ethers / Aryl bromides / Organopnictogen compounds / Organobromides show 2 more
- Substituents
- Alkyl aryl ether / Amine / Amphetamine or derivatives / Anisole / Aralkylamine / Aromatic homomonocyclic compound / Aryl bromide / Aryl halide / Bromobenzene / Dimethoxybenzene show 17 more
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 67WJC4Y2QY
- CAS number
- 32156-26-6
- InChI Key
- FXMWUTGUCAKGQL-UHFFFAOYSA-N
- InChI
- InChI=1S/C11H16BrNO2/c1-7(13)4-8-5-11(15-3)9(12)6-10(8)14-2/h5-7H,4,13H2,1-3H3
- IUPAC Name
- 1-(4-bromo-2,5-dimethoxyphenyl)propan-2-amine
- SMILES
- COC1=CC(Br)=C(OC)C=C1CC(C)N
References
- General References
- Not Available
- External Links
- PubChem Compound
- 62065
- PubChem Substance
- 46507989
- ChemSpider
- 55902
- BindingDB
- 50005257
- ChEMBL
- CHEMBL6607
- Guide to Pharmacology
- GtP Drug Page
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source logP 2.58 HANSCH,C & LEO,AJ (1985) - Predicted Properties
Property Value Source Water Solubility 0.0948 mg/mL ALOGPS logP 2.53 ALOGPS logP 2.26 Chemaxon logS -3.5 ALOGPS pKa (Strongest Basic) 9.9 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 3 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 44.48 Å2 Chemaxon Rotatable Bond Count 4 Chemaxon Refractivity 64.25 m3·mol-1 Chemaxon Polarizability 25.28 Å3 Chemaxon Number of Rings 1 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.9962 Blood Brain Barrier + 0.9475 Caco-2 permeable + 0.7137 P-glycoprotein substrate Non-substrate 0.711 P-glycoprotein inhibitor I Non-inhibitor 0.804 P-glycoprotein inhibitor II Non-inhibitor 0.9441 Renal organic cation transporter Non-inhibitor 0.8015 CYP450 2C9 substrate Non-substrate 0.8693 CYP450 2D6 substrate Substrate 0.6261 CYP450 3A4 substrate Substrate 0.5248 CYP450 1A2 substrate Inhibitor 0.8743 CYP450 2C9 inhibitor Non-inhibitor 0.8389 CYP450 2D6 inhibitor Inhibitor 0.8451 CYP450 2C19 inhibitor Non-inhibitor 0.7714 CYP450 3A4 inhibitor Non-inhibitor 0.7737 CYP450 inhibitory promiscuity High CYP Inhibitory Promiscuity 0.5 Ames test Non AMES toxic 0.5865 Carcinogenicity Non-carcinogens 0.7668 Biodegradation Not ready biodegradable 0.9808 Rat acute toxicity 3.0047 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.8956 hERG inhibition (predictor II) Non-inhibitor 0.617
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS splash10-0006-9060000000-44bf80dac30d104ad6f7 Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-0a4i-0090000000-5ece430b9d06c2b1af29 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-00di-0090000000-90fa9db7444f534321d3 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-05fr-0090000000-7caf81cd2fccbfee1830 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-00b9-8290000000-b1b1bfb3aeb15ddba065 Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-01ry-4970000000-c9d9f60651f1b5807cbd Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-004i-9160000000-5c75f22f9f20b860d6f1 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 147.51878 predictedDeepCCS 1.0 (2019) [M+H]+ 149.87679 predictedDeepCCS 1.0 (2019) [M+Na]+ 156.2959 predictedDeepCCS 1.0 (2019)
Drug created at July 31, 2007 13:09 / Updated at June 12, 2020 16:51